What does DR. GHIJSELS ERIK, NEFROLOOG do?

DR. GHIJSELS ERIK, NEFROLOOG is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Private Limited, started on 31 August 2006, 2 establishments.

What is the address of DR. GHIJSELS ERIK, NEFROLOOG?

The registered office of DR. GHIJSELS ERIK, NEFROLOOG is located at Oudebaan 48, 1790 Affligem.

Is DR. GHIJSELS ERIK, NEFROLOOG still active?

Yes. According to the CBE (30 September 2026) DR. GHIJSELS ERIK, NEFROLOOG is active, legal situation “Normale toestand”, started on 31 August 2006.

Is DR. GHIJSELS ERIK, NEFROLOOG registered on Peppol?

Yes, DR. GHIJSELS ERIK, NEFROLOOG is registered on the Peppol network with ID 0208:0883526082.

What is the enterprise number of DR. GHIJSELS ERIK, NEFROLOOG?

The enterprise number of DR. GHIJSELS ERIK, NEFROLOOG is BE0883526082.

When was DR. GHIJSELS ERIK, NEFROLOOG founded?

DR. GHIJSELS ERIK, NEFROLOOG was founded on 31 August 2006.

Who are the directors of DR. GHIJSELS ERIK, NEFROLOOG?

According to the 2025 annual accounts, the directors of DR. GHIJSELS ERIK, NEFROLOOG are: Erik GHIJSELS.

Is DR. GHIJSELS ERIK, NEFROLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 August 2006; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did DR. GHIJSELS ERIK, NEFROLOOG make in 2025?

DR. GHIJSELS ERIK, NEFROLOOG posted a profit after taxes of € 281,213 in financial year 2025.

What is the revenue of DR. GHIJSELS ERIK, NEFROLOOG?

As a small company, DR. GHIJSELS ERIK, NEFROLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 461,063.

DR. GHIJSELS ERIK, NEFROLOOG (Private Limited) - Affligem

Dossier DR. GHIJSELS ERIK, NEFROLOOG, printed on 30 September 2026 from databakkes.be/en/0883526082/dr-ghijsels-erik-nefroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 32 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

DR. GHIJSELS ERIK, NEFROLOOG from Affligem, company number BE0883526082, closed financial year 2025 with a result of € 281,213 after tax. For that financial year DR. GHIJSELS ERIK, NEFROLOOG recorded a gross margin of € 461,063 and equity of € 99,374. Compared with financial year 2024, the result moved from € 375,248 to € 281,213. The company is profitable. The buffer shrank hard: equity is 90 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 15, 2026.

What it is worth Shrank hard

€ 99,374

▼ 90% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 281,213

▼ 25% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 252,204

▲ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1.2 million paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 15,637

▼ 48% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 768

▼ 56% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 2,672

▼ 89% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 380,896 Gross margin 2022: € 380,896 First fiscal year in the series	€ 463,086 Gross margin 2023: € 463,086 ▲ 22% vs 2022 (€ 380,896) Favourable step	€ 580,887 Gross margin 2024: € 580,887 ▲ 25% vs 2023 (€ 463,086) Favourable step	€ 461,063 Gross margin 2025: € 461,063 ▼ 21% vs 2024 (€ 580,887) Unfavourable step	▼ 21%
Profit after taxes	€ 149,991 Profit after taxes 2022: € 149,991 First fiscal year in the series	€ 296,867 Profit after taxes 2023: € 296,867 ▲ 98% vs 2022 (€ 149,991) Favourable step	€ 375,248 Profit after taxes 2024: € 375,248 ▲ 26% vs 2023 (€ 296,867) Favourable step	€ 281,213 Profit after taxes 2025: € 281,213 ▼ 25% vs 2024 (€ 375,248) Unfavourable step	▼ 25%
Equity	€ 957,570 Equity 2022: € 957,570 First fiscal year in the series	€ 1,004,011 Equity 2023: € 1,004,011 ▲ 5% vs 2022 (€ 957,570) Favourable step	€ 1,014,089 Equity 2024: € 1,014,089 ▲ 1% vs 2023 (€ 1,004,011) Favourable step	€ 99,374 Equity 2025: € 99,374 ▼ 90% vs 2024 (€ 1,014,089) Unfavourable step	▼ 90%
Total debts	€ 696,725 Total debts 2022: € 696,725 First fiscal year in the series	€ 310,791 Total debts 2023: € 310,791 ▼ 55% vs 2022 (€ 696,725) Favourable step	€ 189,803 Total debts 2024: € 189,803 ▼ 39% vs 2023 (€ 310,791) Favourable step	€ 1,077,796 Total debts 2025: € 1,077,796 ▲ € 887,993 vs 2024 (€ 189,803) Unfavourable step	▲ € 887,993
Cash	€ 231,277 Cash 2022: € 231,277 First fiscal year in the series	€ 191,443 Cash 2023: € 191,443 ▼ 17% vs 2022 (€ 231,277) Unfavourable step	€ 172,069 Cash 2024: € 172,069 ▼ 10% vs 2023 (€ 191,443) Unfavourable step	€ 252,204 Cash 2025: € 252,204 ▲ 47% vs 2024 (€ 172,069) Favourable step	▲ 47%
Land & buildings	€ 947,050 Land & buildings 2022: € 947,050 First fiscal year in the series	€ 918,842 Land & buildings 2023: € 918,842 ▼ 3% vs 2022 (€ 947,050) Unchanged	€ 866,946 Land & buildings 2024: € 866,946 ▼ 6% vs 2023 (€ 918,842) Unchanged	€ 815,051 Land & buildings 2025: € 815,051 ▼ 6% vs 2024 (€ 866,946) Unchanged	▼ 6%
Retained profit	€ 858,990 Retained profit 2022: € 858,990 First fiscal year in the series	€ 905,431 Retained profit 2023: € 905,431 ▲ 5% vs 2022 (€ 858,990) Favourable step	€ 915,509 Retained profit 2024: € 915,509 ▲ 1% vs 2023 (€ 905,431) Favourable step	€ 794 Retained profit 2025: € 794 ▼ € 914,716 vs 2024 (€ 915,509) Unfavourable step	▼ € 914,716
Dividend	€ 500,002 Dividend 2022: € 500,002 First fiscal year in the series	€ 250,425 Dividend 2023: € 250,425 ▼ 50% vs 2022 (€ 500,002) Unchanged	€ 365,170 Dividend 2024: € 365,170 ▲ 46% vs 2023 (€ 250,425) Unchanged	€ 1,195,929 Dividend 2025: € 1,195,929 ▲ 227% vs 2024 (€ 365,170) Unchanged	▲ 227%
Balance sheet total	€ 1,732,324 Balance sheet total 2022: € 1,732,324 First fiscal year in the series	€ 1,314,802 Balance sheet total 2023: € 1,314,802 ▼ 24% vs 2022 (€ 1,732,324) Unchanged	€ 1,203,892 Balance sheet total 2024: € 1,203,892 ▼ 8% vs 2023 (€ 1,314,802) Unchanged	€ 1,177,170 Balance sheet total 2025: € 1,177,170 ▼ 2% vs 2024 (€ 1,203,892) Unchanged	▼ 2%

Key figures of DR. GHIJSELS ERIK, NEFROLOOG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to DR. GHIJSELS ERIK, NEFROLOOG?

What happened at DR. GHIJSELS ERIK, NEFROLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 15, 2026 New annual accounts for financial year 2025: profit of € 281,213 (▼ 25% vs 2024). Source: NBB ↗
2006 Erik GHIJSELS became a director. NBB
Aug 31, 2006 New establishment in Affligem. KBO
Aug 31, 2006 New establishment in Aalst. KBO
Aug 31, 2006 Start of the company according to the CBE. KBO

In short

From € 149,991 profit in 2022 to € 281,213 profit in 2025.

Paid € 346,504 in corporate taxes since 2022.

Best year ever: 2024, with € 375,248 profit.

Paid out € 2.3 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. GHIJSELS ERIK, NEFROLOOG? We notify you, reason included.

Follow DR. GHIJSELS ERIK, NEFROLOOG

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Erik GHIJSELS

DR. GHIJSELS ERIK, NEFROLOOG

Behind DR. GHIJSELS ERIK, NEFROLOOG is Erik GHIJSELS.

See the full network in the app

Directors

According to the 2025 annual accounts

Erik GHIJSELS

Director

since 2006

Establishments

Establishment units

Physical locations of this company

Registered office

Oudebaan 48

1790 Affligem

2.199.626.141

Moorselbaan 164

9300 Aalst

Active since 31 August 2006

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0883.526.082
VAT number: BE 0883.526.082
Registered office: Oudebaan 48, 1790 Affligem
Names & denominations: DR. GHIJSELS ERIK, NEFROLOOG
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 31 August 2006
Peppol: Active · Active since 25 Nov 2024
Activities · NACE: Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗